143 related articles for article (PubMed ID: 27020306)
1. Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.
Wu X; Fang Z; Yang B; Zhong L; Yang Q; Zhang C; Huang S; Xiang R; Suzuki T; Li LL; Yang SY
Bioorg Med Chem Lett; 2016 May; 26(9):2284-8. PubMed ID: 27020306
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
3. Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors.
Fang Z; Wang TQ; Li H; Zhang G; Wu XA; Yang L; Peng YL; Zou J; Li LL; Xiang R; Yang SY
Bioorg Med Chem Lett; 2017 Jul; 27(14):3201-3204. PubMed ID: 28539219
[TBL] [Abstract][Full Text] [Related]
4. Identification of potent, selective KDM5 inhibitors.
Gehling VS; Bellon SF; Harmange JC; LeBlanc Y; Poy F; Odate S; Buker S; Lan F; Arora S; Williamson KE; Sandy P; Cummings RT; Bailey CM; Bergeron L; Mao W; Gustafson A; Liu Y; VanderPorten E; Audia JE; Trojer P; Albrecht BK
Bioorg Med Chem Lett; 2016 Sep; 26(17):4350-4. PubMed ID: 27476424
[TBL] [Abstract][Full Text] [Related]
5. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
[TBL] [Abstract][Full Text] [Related]
6. Identification of ryuvidine as a KDM5A inhibitor.
Mitsui E; Yoshida S; Shinoda Y; Matsumori Y; Tsujii H; Tsuchida M; Wada S; Hasegawa M; Ito A; Mino K; Onuki T; Yoshida M; Sasaki R; Mizukami T
Sci Rep; 2019 Jul; 9(1):9952. PubMed ID: 31289306
[TBL] [Abstract][Full Text] [Related]
7. Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.
Labadie SS; Dragovich PS; Cummings RT; Deshmukh G; Gustafson A; Han N; Harmange JC; Kiefer JR; Li Y; Liang J; Liederer BM; Liu Y; Manieri W; Mao W; Murray L; Ortwine DF; Trojer P; VanderPorten E; Vinogradova M; Wen L
Bioorg Med Chem Lett; 2016 Sep; 26(18):4492-4496. PubMed ID: 27499454
[TBL] [Abstract][Full Text] [Related]
8. A computer aided drug discovery based discovery of lead-like compounds against KDM5A for cancers using pharmacophore modeling and high-throughput virtual screening.
Tariq A; Rehman HM; Mateen RM; Ali M; Mutahir Z; Afzal MS; Sajjad M; Gul R; Saleem M
Proteins; 2022 Mar; 90(3):645-657. PubMed ID: 34642975
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.
Horton JR; Liu X; Gale M; Wu L; Shanks JR; Zhang X; Webber PJ; Bell JSK; Kales SC; Mott BT; Rai G; Jansen DJ; Henderson MJ; Urban DJ; Hall MD; Simeonov A; Maloney DJ; Johns MA; Fu H; Jadhav A; Vertino PM; Yan Q; Cheng X
Cell Chem Biol; 2016 Jul; 23(7):769-781. PubMed ID: 27427228
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of KDM5A in human cancer.
Yang GJ; Zhu MH; Lu XJ; Liu YJ; Lu JF; Leung CH; Ma DL; Chen J
J Hematol Oncol; 2021 Feb; 14(1):30. PubMed ID: 33596982
[TBL] [Abstract][Full Text] [Related]
11. Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism.
Torres IO; Kuchenbecker KM; Nnadi CI; Fletterick RJ; Kelly MJ; Fujimori DG
Nat Commun; 2015 Feb; 6():6204. PubMed ID: 25686748
[TBL] [Abstract][Full Text] [Related]
12. From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Liang J; Labadie S; Zhang B; Ortwine DF; Patel S; Vinogradova M; Kiefer JR; Mauer T; Gehling VS; Harmange JC; Cummings R; Lai T; Liao J; Zheng X; Liu Y; Gustafson A; Van der Porten E; Mao W; Liederer BM; Deshmukh G; An L; Ran Y; Classon M; Trojer P; Dragovich PS; Murray L
Bioorg Med Chem Lett; 2017 Jul; 27(13):2974-2981. PubMed ID: 28512031
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
Yang GJ; Ko CN; Zhong HJ; Leung CH; Ma DL
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30650517
[TBL] [Abstract][Full Text] [Related]
14. Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.
Yang GJ; Wang W; Mok SWF; Wu C; Law BYK; Miao XM; Wu KJ; Zhong HJ; Wong CY; Wong VKW; Ma DL; Leung CH
Angew Chem Int Ed Engl; 2018 Oct; 57(40):13091-13095. PubMed ID: 29968419
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a new class of JMJD6 inhibitors and structure-activity relationship study.
Wang T; Zhang R; Liu Y; Fang Z; Zhang H; Fan Y; Yang S; Xiang R
Bioorg Med Chem Lett; 2021 Jul; 44():128109. PubMed ID: 33991627
[TBL] [Abstract][Full Text] [Related]
16. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
Vinogradova M; Gehling VS; Gustafson A; Arora S; Tindell CA; Wilson C; Williamson KE; Guler GD; Gangurde P; Manieri W; Busby J; Flynn EM; Lan F; Kim HJ; Odate S; Cochran AG; Liu Y; Wongchenko M; Yang Y; Cheung TK; Maile TM; Lau T; Costa M; Hegde GV; Jackson E; Pitti R; Arnott D; Bailey C; Bellon S; Cummings RT; Albrecht BK; Harmange JC; Kiefer JR; Trojer P; Classon M
Nat Chem Biol; 2016 Jul; 12(7):531-8. PubMed ID: 27214401
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of KDM5A for cancer treatment.
Yang GJ; Wu J; Miao L; Zhu MH; Zhou QJ; Lu XJ; Lu JF; Leung CH; Ma DL; Chen J
Eur J Med Chem; 2021 Dec; 226():113855. PubMed ID: 34555614
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic QSAR modeling derived virtual screening, drug repurposing, ADMET and
Jawarkar RD; Zaki MEA; Al-Hussain SA; Al-Mutairi AA; Samad A; Masand V; Humane V; Mali S; Alzahrani AYA; Rashid S; Elossaily GM
J Biomol Struct Dyn; 2024 Feb; ():1-31. PubMed ID: 38385447
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
Horton JR; Woodcock CB; Chen Q; Liu X; Zhang X; Shanks J; Rai G; Mott BT; Jansen DJ; Kales SC; Henderson MJ; Cyr M; Pohida K; Hu X; Shah P; Xu X; Jadhav A; Maloney DJ; Hall MD; Simeonov A; Fu H; Vertino PM; Cheng X
J Med Chem; 2018 Dec; 61(23):10588-10601. PubMed ID: 30392349
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening.
Meng F; Cheng S; Ding H; Liu S; Liu Y; Zhu K; Chen S; Lu J; Xie Y; Li L; Liu R; Shi Z; Zhou Y; Liu YC; Zheng M; Jiang H; Lu W; Liu H; Luo C
J Med Chem; 2015 Oct; 58(20):8166-81. PubMed ID: 26390175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
